Abstract
Objective
Recent studies showed that a structured patient therapeutic education (PTE) may decrease both mortality and the development of diabetes complications. Nevertheless, no data are available in the literature on the impact of individual PTE on the complications in newly diagnosed type 2 diabetic patients. Aim of the present randomized controlled trial is to evaluate the impact of individual PTE on the occurrence of macrovascular complications in newly diagnosed type 2 diabetic patients when compared to usual care (UC) and group PTE.
Design and methods
Six hundred newly diagnosed type 2 diabetic patients will be enrolled. The patients will be randomly assigned to one of these three groups: individual PTE, group PTE and UC. A comprehensive and complete PTE will be delivered to all the patients: PTE will include eleven themes. Primary composite endpoint of the study is occurrence of vascular complications, including cardiovascular death, non fatal coronary disease, non fatal stroke, peripheral artery disease. Secondary endpoints are: foot ulcers, amputations, sexual dysfunction, quality of life, microvascular complications, bone health, intensification of diabetes and hypertension therapy.
Results and Conclusions
The present trial can give precious information on the features for the most effective PTE.
Similar content being viewed by others
References
A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine. 53, 18–27 (2016)
C.K. Wong, W.C. Wong, E.Y. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP). Endocrine 53(2):412–422 (2016)
X. He, J. Li, B. Wang, Q. Yao, L. Li, R. Song, X. Shi, J.A. Zhang, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine 55(3), 712–731 (2017)
C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero, A. Garzaniti, G. Pelissero, S. Collaviti, A. Grugnetti, P. Gallotti, A. Pujia, S.B. Solerte, A. Giustina, Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41(1), 89–95 (2012)
C. Gazzaruso, A. Pujia, S.B. Solerte, E.D. Amici, E. Emanuele, C. Falcone, D. Geroldi, A. Giustina, A. Garzaniti, Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int. J. Impot. Res. 18(3), 311–315 (2006)
C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, P. Gallotti, A. Pujia, S.B. Solerte, G. Pelissero, A. Giustina, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. Diabetes Care 36(6), 1720–1725 (2013)
C. Gazzaruso, A. Coppola, T. Montalcini, C. Valenti, A. Garzaniti, G. Pelissero, F. Salvucci, P. Gallotti, A. Pujia, C. Falcone, S.B. Solerte, A. Giustina, Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 40(2), 273–279 (2011)
C. Gazzaruso, A. Coppola, T. Montalcini, C. Valenti, G. Pelissero, S.B. Solerte, F. Salvucci, P. Gallotti, A. Pujia, A. Garzaniti, A. Giustina, Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients. Intern. Emerg. Med. 7(3), 257–266 (2012)
C. Gazzaruso, A. Garzaniti, P. Buscaglia, G. D’Annunzio, A. Porta, G. Vandelli, R. Lorini, G. Finardi, P. Fratino, D. Geroldi, Lipoprotein(a) levels and apolipoprotein(a) polymorphism in type 1 diabetes mellitus: relationships to microvascular and neurological complications. Acta Diabetol. 35(1), 13–18 (1998)
Questionario sullo stato di salute SF-36 (V1), Standard 12/94 IQOLA SF-36 Italian Version 1.6 http://crc.marionegri.it/qdv/downloads/SF36
T. Montalcini, P. Gallotti, A. Coppola, V. Zambianchi, M. Fodaro, E. Galliera, M.G. Marazzi, S. Romeo, S. Giannini, M.M. Corsi Romanelli, A. Pujia, C. Gazzaruso, Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes. Osteoporos. Int. 26(5), 1639–1646 (2015)
S. Bossoni, G. Mazziotti, C. Gazzaruso, D. Martinelli, S. Orini, S.B. Solerte, G. Romanelli, A. Giustina, Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. Age Ageing 37(2), 222–225 (2008)
C. Gazzaruso, M. Fodaro, A. Coppola, Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications? Endocrine 53(2), 347–349 (2016)
S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse, LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016)
B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
The present trial complies with ethical requirements.
Informed consent
Informed consent will be required to any patient will be recruited.
Rights and permissions
About this article
Cite this article
Coppola, A., Luzi, L., Montalcini, T. et al. Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the INdividual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial. Endocrine 60, 46–49 (2018). https://doi.org/10.1007/s12020-017-1427-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1427-x